# Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Study · id `cardio:ct-nct02525939` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02525939](<https://clinicaltrials.gov/study/NCT02525939>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02525939

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6147 participants.

## Technical summary

Registry record NCT02525939. Randomized; quadruple masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2021-10 (actual). Results posted on 2022-10-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6147 participants (enrolled count; ClinicalTrials.gov record NCT02525939, source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)
- Started: 2016-04 (actual) (ClinicalTrials.gov record NCT02525939, source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)
- Primary completion: 2021-10 (actual) (ClinicalTrials.gov record NCT02525939, source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)
- Completion: 2021-10 (actual) (ClinicalTrials.gov record NCT02525939, source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)
- Results first posted: 2022-10-12 (ClinicalTrials.gov record NCT02525939, source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Czechia; Denmark; Finland; France; Germany; Hungary; Israel; Italy; Netherlands; New Zealand; Poland; Portugal; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Sweden; Switzerland; Türkiye; United Arab Emirates; United Kingdom (ClinicalTrials.gov record NCT02525939, source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02525939-2022-10-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
- Acronym: dal-GenE
- Condition: Acute Coronary Syndrome
- Intervention (Drug): dalcetrapib
- Intervention (Drug): Placebo
- Lead sponsor: DalCor Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: The Montreal Health Innovations Coordinating Center (MHICC)
- Collaborator class: OTHER
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Roche Molecular Systems, Inc
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as a collaborator: The Montreal Health Innovations Coordinating Center (MHICC) (`cardio:org-the-montreal-health-innovations-coordinating-center-mhicc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial (`cardio:pubmed-35856777`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 43990e8b2ef053b4d41784c2b1b33470be7c138ae8908f3e9753311650b84a6f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
